FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).

JS Zager; M Orloff; PF Ferrucci; ES Glazer; A Ejaz; Erika Richtig; S Ochsenreither; MC Lowe; S Reddy; GM Beasley; A Gesierich; R Dummer; A Arance; SW Fenwick; M Wheater; C Ottensmeier

FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).

JS Zager
, M Orloff
, PF Ferrucci
, ES Glazer
, A Ejaz
, Erika Richtig
, S Ochsenreither
, MC Lowe
, S Reddy
, GM Beasley
, A Gesierich
, R Dummer
, A Arance
, SW Fenwick
, M Wheater
, C Ottensmeier

Department of Dermatology and Venereology

Research output: Contribution to conference book › Conference article

Original language	English
Publication status	Published - 2022
Event	ASCO - Chicago, United States Duration: 3 Jun 2022 → 7 Jun 2022

Conference

Conference	ASCO
Country/Territory	United States
City	Chicago
Period	3/06/22 → 7/06/22

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

302 Clinical Medicine

FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).
Zager, J. (Author), Orloff, M. (Author), Ferrucci, P. (Author), Glazer, E. (Author), Ejaz, A. (Author), Richtig, E. (Author), Ochsenreither, S. (Author), Lowe, M. (Author), Reddy, S. (Author), Beasley, G. (Author), Gesierich, A. (Author), Dummer, R. (Author), Arance, A. (Author), Fenwick, S. (Author), Wheater, M. (Author) & Ottensmeier, C. (Author)
2022
Activity: Talk, presentation or poster › Poster

Cite this

Zager, JS., Orloff, M., Ferrucci, PF., Glazer, ES., Ejaz, A., Richtig, E., Ochsenreither, S., Lowe, MC., Reddy, S., Beasley, GM., Gesierich, A., Dummer, R., Arance, A., Fenwick, SW., Wheater, M., & Ottensmeier, C. (2022). FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).. Paper presented at ASCO, Chicago, United States.

@conference{4cb7b2208d144fee8d4d130279d8d45f,

title = "FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).",

author = "JS Zager and M Orloff and PF Ferrucci and ES Glazer and A Ejaz and Erika Richtig and S Ochsenreither and MC Lowe and S Reddy and GM Beasley and A Gesierich and R Dummer and A Arance and SW Fenwick and M Wheater and C Ottensmeier",

year = "2022",

language = "English",

note = "ASCO ; Conference date: 03-06-2022 Through 07-06-2022",

}

Zager, JS, Orloff, M, Ferrucci, PF, Glazer, ES, Ejaz, A, Richtig, E, Ochsenreither, S, Lowe, MC, Reddy, S, Beasley, GM, Gesierich, A, Dummer, R, Arance, A, Fenwick, SW, Wheater, M & Ottensmeier, C 2022, 'FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).', Paper presented at ASCO, Chicago, United States, 3/06/22 - 7/06/22.

TY - CONF

T1 - FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).

AU - Zager, JS

AU - Orloff, M

AU - Ferrucci, PF

AU - Glazer, ES

AU - Ejaz, A

AU - Richtig, Erika

AU - Ochsenreither, S

AU - Lowe, MC

AU - Reddy, S

AU - Beasley, GM

AU - Gesierich, A

AU - Dummer, R

AU - Arance, A

AU - Fenwick, SW

AU - Wheater, M

AU - Ottensmeier, C

PY - 2022

Y1 - 2022

M3 - Conference article

T2 - ASCO

Y2 - 3 June 2022 through 7 June 2022

ER -

FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).

Conference

UN SDGs

Branches of science

Activities

FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A).

Cite this